Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) generates a steady flow of news related to its late-stage biopharmaceutical pipeline in ophthalmology and neuro-ophthalmology. Company announcements highlight clinical trial milestones, regulatory designations, capital markets activity, and scientific presentations that are relevant for investors and observers tracking developments in optic neuropathies and retinal disease.
Recent news releases describe the advancement of Privosegtor, a peptoid small-molecule neuroprotective candidate, into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy. Oculis has reported positive Phase 2 ACUITY data in acute optic neuritis and disclosed that Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Orphan Drug designation from the FDA and EMA. Updates often cover trial design, endpoints such as low-contrast visual acuity, and planned global enrollment.
News coverage also follows OCS-01 eye drops in Phase 3 DIAMOND studies for diabetic macular edema, including the use of the company’s OPTIREACH technology to deliver dexamethasone topically to the retina. In addition, Oculis issues releases on Licaminlimab for dry eye disease, participation in major medical meetings such as the J.P. Morgan Healthcare Conference and ophthalmology congresses, and insider transaction notifications related to restricted stock unit vesting and director share purchases.
For readers monitoring OCS, this news feed provides company-sourced updates on clinical progress, regulatory interactions, financing transactions disclosed in Form 6-K filings, and scientific data presentations. It can be a useful reference for following how Oculis advances its investigational therapies for optic neuritis, NAION, diabetic macular edema, and dry eye disease over time.
Oculis Holding AG (Nasdaq: OCS) announced that updates on its DIAMOND Phase 3 program for OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop for diabetic macular edema (DME), will be presented at two upcoming events. Dr. David Eichenbaum will present at Innovate Retina, while Dr. Riad Sherif, Oculis' CEO, will present at Eyecelerator 2024.
Both presentations will highlight the robust results from Stage 1 of the DIAMOND program at Week 12 and present the design of Stage 2, which will assess efficacy and safety at Week 52. The ongoing DIAMOND-1 and DIAMOND-2 Phase 3 trials aim to enroll 350 patients each. Additionally, Dr. Sherif will discuss upcoming milestones, including topline results from the ACUITY Phase 2 trial with OCS-05 for acute optic neuritis, expected before the end of 2024.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has appointed Daniel S. Char as Chief Legal Officer. Mr. Char brings over 35 years of global legal leadership experience in biotech and medical device companies. He will lead Oculis' legal, compliance, and corporate governance functions.
This appointment aligns with Oculis' strategic plan to advance its innovative pipeline, particularly OCS-01, the first topical eye drop in retina. Mr. Char's extensive expertise includes corporate governance, compliance, drug development and commercialization, financing, licensing, and M&A transactions.
Prior to joining Oculis, Mr. Char served as Chief Legal Officer at ImmunoGen and General Counsel at Evelo Biosciences. He has also held senior legal positions at Smith & Nephew, Targanta Therapeutics, and Biogen. Mr. Char holds a Juris Doctor from Harvard Law School and a Bachelor of Arts in Economics from Tufts University.
Oculis Holding AG (Nasdaq: OCS) and EURETINA have announced Dr. Andrea Govetto as the winner of the inaugural Ramin Tadayoni Award. This award, established in memory of Oculis' late Chief Scientific Officer, aims to support outstanding retina research. Dr. Govetto's winning project focuses on developing a computational model of fluid flow and retinal tissue deformation in macular edema.
The award, presented at the EURETINA congress in Barcelona, includes €30,000 for research support and an additional €5,000 for the awardee. It recognizes promising ophthalmologists in retina research, honoring Prof. Tadayoni's legacy. Dr. Govetto, a vitreoretinal surgeon at Oftalmico-Fatebenefratelli Hospital in Milan, was selected from over 50 competitive submissions.
Oculis CEO, Dr. Riad Sherif, expressed pride in supporting the award and advancing retinal disease research. EURETINA President, Dr. Anat Loewenstein, congratulated Dr. Govetto and highlighted the award's significance in furthering Prof. Tadayoni's contributions to the field.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has announced its participation in three major investor conferences in September 2024:
1. Wells Fargo Healthcare Conference (September 4-6, Boston, MA)
2. H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, New York, NY)
3. Baird Global Healthcare Conference (September 10-11, New York, NY)
Key presentations include CEO Riad Sherif at H.C. Wainwright on September 11 at 9:30 am ET, and CFO Sylvia Cheung at Baird on September 10 at 9:05 am ET. The company will be available for one-on-one meetings during these events. Presentation links will be posted on Oculis' website under the Investors & Media section.
Oculis, a Swiss-based pharmaceutical company trading under the symbol OCS, has filed its Q2 Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) with the SEC on Form 6-K. This follows an earlier press release announcing the same. The filings provide detailed financial information and management's perspective on the company's performance for the second quarter of 2024. Investors and analysts can now access these documents to gain deeper insights into Oculis's financial health, operational performance, and strategic direction.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) reported Q2 2024 financial results and provided company updates. Key highlights include:
1. Positive topline results from Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease
2. Phase 2 ACUITY trial of OCS-05 for acute optic neuritis on track for Q4 2024 readout
3. Pre-NDA meeting with FDA completed for OCS-01 in post-operative inflammation and pain
4. Cash position of $131.2 million as of June 30, 2024, providing runway into 2H 2026
5. Q2 net loss of $23.0 million, compared to $14.3 million in Q2 2023
6. Raised $59 million in an oversubscribed registered direct offering
The company continues to advance its clinical programs, with strong momentum in DIAMOND-1 and DIAMOND-2 trials for DME.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) reported Q2 2024 financial results and provided a company update. Key highlights include:
1. Positive topline results from Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease
2. Phase 2 ACUITY trial of OCS-05 for acute optic neuritis on track for Q4 2024 readout
3. Pre-NDA meeting completed for OCS-01 in post-operative inflammation and pain, with NDA submission planned for Q1 2025
4. Cash position of $131.2 million as of June 30, 2024, providing runway into 2H 2026
5. Q2 net loss of $23.0 million, primarily due to increased clinical development expenses
6. Continued progress in Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has appointed Dr. Sharon Klier as Chief Development Officer. With over 20 years of experience in ophthalmology clinical development, Dr. Klier will oversee Oculis' ophthalmology pipeline. Her expertise spans early and late-stage programs, regulatory submissions, and approvals, particularly in retinal diseases, neuro-ophthalmology, and ocular inflammation.
Prior to joining Oculis, Dr. Klier served as Chief Development Officer, Head of Ophthalmology at UNITY Biotechnology. She has also held roles at Quark, Allergan, ISTA, and Pfizer. Oculis CEO Dr. Riad Sherif expressed confidence that Dr. Klier's expertise will be important in progressing the company's late-stage pipeline and executing its strategic vision.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical firm focused on eye care, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
Riad Sherif, M.D., CEO of Oculis, will join a panel discussion titled 'Derisked Late-stage Candidates for Retinal Disorders' on August 15, 2024, at 11:00 am ET.
Additionally, Dr. Sherif will give a virtual company presentation available on-demand starting August 15, 2024, at 7:00 am ET.
Access to the presentation and panel discussion will be available through the Oculis website under the Events & Presentation page in the Investors & Media section.
Sabre Gold announced the results of its 2024 Annual General Meeting, held on May 29, 2024. Shareholders approved all agenda items and elected new board members, including Robert K. Warner and Arshad M. Khanani. Additionally, Baruch D. Kuppermann and Frank G. Holz were appointed to the Scientific Advisory Board. The company established a CHF 50 million flexible loan facility with BlackRock, providing significant financial flexibility, though no amounts were drawn at signing. The shareholders approved compensation packages for the Board and Executive Committee, including non-performance-related and variable compensations, as well as equity-based incentives. The company reported a loss of CHF 41.4 million for 2023, which will be carried forward. Key amendments to the articles of association were also approved, including the creation of conditional share capital for bonds and employee incentives.